von Hippel–Lindau disease: A clinical and scientific review

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Human Genetics

• Publication date

  2011-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ejhg.2010.175PMID 21386872PMCID PMC3110036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic comparison of sporadic and syndromic pancreatic islet cell tumors.

  2010cited by this paper
• Psychosocial impact of Von Hippel–Lindau disease: levels and sources of distress

  2010cited by this paper
• Genetic analysis of von Hippel‐Lindau disease

  2010cited by this paper
• Bilateral papillary cystadenoma of the mesosalpinx: a rare manifestation of Von Hippel–Lindau disease

  2010cited by this paper
• Alu‐Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype–phenotype correlations in VHL patients

  2009cited by this paper
• Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.

  2009cited by this paper
• Treatment of kidney cancer

  2009cited by this paper
• Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.

  2009cited by this paper
• Renal cell carcinoma

  2009cited by this paper
• Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma

  2009cited by this paper
• Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease.

  2008cited by this paper
• Endocrine Pancreatic Tumors in von Hippel-Lindau Disease: Clinical, Histological, and Genetic Features

  2008cited by this paper
• Renal cell carcinoma

  2007cited by this paper
• von Hippel-Lindau Disease-Associated Hemangioblastomas Are Derived from Embryologic Multipotent Cells

  2007cited by this paper
• Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel‐Lindau patients

  2007cited by this paper
• Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs).

  2007cited by this paper
• Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

  2006cited by this paper
• Von Hippel-Lindau disease and endocrine tumour susceptibility.

  2006cited by this paper
• Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.

  2005cited by this paper
• Von Hippel-Lindau disease.

  2004cited by this paper
• Genotype–phenotype correlations in von Hippel‐Lindau disease

  2004cited by this paper
• Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.

  2004cited by this paper
• The worldwide distribution of the VHL 598C>T mutation indicates a single founding event.

  2004cited by this paper
• Von Hippel-Lindau disease.

  2004cited by this paper
• Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location

  2004cited by this paper
• The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease.

  2003cited by this paper
• Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.

  2003cited by this paper
• von Hippel-Lindau disease.

  2003cited by this paper
• Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease.

  2003cited by this paper
• Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau's disease: a single center experience.

  2003cited by this paper
• Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

  2002cited by this paper
• HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

  2002cited by this paper
• Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.

  2002cited by this paper
• Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

  2002cited by this paper
• Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.

  2002cited by this paper
• Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

  2002cited by this paper
• Endoscopic Treatment of Solitary, Bilateral, Multiple, and Recurrent Pheochromocytomas and Paragangliomas

  2002cited by this paper
• Germ-line mutations in nonsyndromic pheochromocytoma.

  2002cited by this paper
• The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

  2002cited by this paper
• Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation

  2001cited by this paper
• von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

  2001cited by this paper
• HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing

  2001cited by this paper
• Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

  2001cited by this paper
• Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease

  2000cited by this paper
• Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau.

  2000cited by this paper
• Comparative sequence analysis of the VHL tumor suppressor gene.

  2000cited by this paper
• Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery.

  1999cited by this paper
• Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.

  1999cited by this paper
• Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

  1999cited by this paper
• Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.

  1999cited by this paper
• Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation.

  1999cited by this paper
• The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

  1999cited by this paper
• Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma.

  1999cited by this paper
• Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma.

  1998cited by this paper
• An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.

  1998cited by this paper
• pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.

  1998cited by this paper
• Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.

  1997cited by this paper
• Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease.

  1997cited by this paper
• Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease.

  1997cited by this paper
• Epididymal cystadenomas in von Hippel-Lindau disease.

  1997cited by this paper
• Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.

  1997cited by this paper
• Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.

  1996cited by this paper
• Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.

  1996cited by this paper
• Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect

  1995cited by this paper
• Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene.

  1995cited by this paper
• Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study.

  1995cited by this paper
• Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype

  1995cited by this paper
• Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.

  1994cited by this paper
• Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

  1994cited by this paper
• Mutations of the VHL tumour suppressor gene in renal carcinoma

  1994cited by this paper
• Identification of the von Hippel-Lindau disease tumor suppressor gene.

  1993cited by this paper
• Von Hippel-Lindau disease and renal cell carcinoma in a 16-year-old boy.

  1992cited by this paper
• The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients.

  1992cited by this paper
• Von Hippel-Lindau disease: a genetic study.

  1991cited by this paper
• Clustering of features and genetics of von Hippel-Lindau syndrome.

  1991cited by this paper
• Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.

  1990cited by this paper
• Clinical features and natural history of von Hippel-Lindau disease.

  1990cited by this paper

• Consideration of inherited cancer risk on a continuum: An international and multidisciplinary perspective: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).

  2026cites this paper
• Diagnosis of Von Hippel-Lindau Syndrome Via Pancreatic Cyst Fluid Next-Generation Sequencing.

  2026cites this paper
• Hereditary renal cell carcinoma surveillance protocols: a review of the literature and proposed recommendations

  2026cites this paper
• 5′ UTR length regulates alternative N-terminal protein isoform production in health and disease

  2026cites this paper
• Insights from 2057 germline genetic tests in renal cell carcinoma patients support revisiting testing criteria.

  2026cites this paper
• Synchronous giant bilateral renal tumors as initial presentation of Von Hippel-Lindau disease: Sequential surgical management and transition to renal replacement therapy

  2025cites this paper
• Quantification of Belzutifan in Biological Samples: LC-MS/MS Method Validation and Pharmacokinetic Study in Rats.

  2025cites this paper
• The gradual expansion of multiple intramedullary metastatic renal cell carcinoma in a patient with von Hippel–Lindau disease with multiple intramedullary hemangioblastomas: illustrative case

  2025cites this paper
• Genetic Testing and Counselling for Hereditary Renal Carcinoma: What Do Clinicians Need to Know?

  2025cites this paper
• From surgery to systemic therapy: long-term lessons of belzutifan in von Hippel-Lindau disease

  2025cites this paper
• Pancreatic Hemangioblastoma in a Patient with von Hippel-Lindau Disease: A Case Report

  2025cites this paper
• Multi-Platform Curation in the Development of ACMG/AMP Specifications for Von Hippel Lindau (VHL) Disease

  2025cites this paper
• Demographics, Clinical Profiles, and Outcomes of Patients With Adrenal Disorders in a Tertiary Care Center: A Retrospective Study

  2025cites this paper
• Retinal cavernous hemangioma – A rare differential

  2025cites this paper
• Pathogenicity of germline VHL variants is associated with renal cell carcinoma size in von Hippel-Lindau disease

  2025cites this paper
• Isoechoic Renal Tumors: A Case Report and Literature Review

  2025cites this paper
• From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004

  2025cites this paper
• Role of Targeted Therapy in the Management of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: A Single-Proportion Meta-Analysis

  2025cites this paper
• Centripetal filling and pathological insights: a rare case of sporadic renal hemangioblastoma with literature review

  2025cites this paper
• Germline Mutations as Cancer Drug Targets.

  2025cites this paper
• Re: W. Marston Linehan, Cathy Anne Pinto, Yanfang Liu, et al. Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease. Eur Urol 2025;88:56-63.

  2025cites this paper
• Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

  2025cites this paper
• Von Hippel-Lindau Disease : A Comprehensive Review of Diagnosis, Genetics, Clinical Challenges, and Surveillance

  2025cites this paper
• Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures

  2025cites this paper
• Inherited Susceptibility to Cancer: Past, Present and Future

  2025cites this paper
• Diagnosis and treatment of Von Hippel-Lindau syndrome: A case series

  2025cites this paper
• Novel Von Hippel-Lindau Germline Variants in Iranian Patients with Retinal Capillary Hemangioblastoma

  2025cites this paper
• A schema for sporadic and heritable disease pathogenesis integrating spatiotemporal distribution with the character of genetic variants

  2025cites this paper
• Novel OCT Angiography Features, von Hippel–Lindau Disease Association, and Genetic Characterization of Juxtapapillary Retinal Capillary Hemangiomas

  2025cites this paper
• Narrative Review of Von Hippel-Lindau Syndrome: From Discovery to Modern Medical and Surgical Therapies

  2025cites this paper
• Genotype-specific neoplastic risk profiles in patients with VHL disease

  2025cites this paper
• Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions

  2025cites this paper
• Progressive Spinal and Cerebellar Multifocal Hemangioblastoma in Von Hippel-Lindau Disease: Case Report and Literature Review

  2025cites this paper
• Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors – a retrospective single center analysis

  2025cites this paper
• Multigenerational VHL family characterized by pathogenic germline ELOC variant: Response to belzutifan.

  2025cites this paper
• Von Hippel-Lindau Syndrome

  2025cites this paper
• New Developments in VHL-Associated Neuroendocrine Neoplasms

  2025cites this paper
• Epigenetic Insights into Tuberous Sclerosis Complex, Von Hippel–Lindau Syndrome, and Ataxia–Telangiectasia

  2025cites this paper
• French recommendations on multi-gene panel testing in renal cell carcinoma.

  2025cites this paper
• Impact of Belzutifan on Pancreatic Cystic Lesions and Neuroendocrine Tumors in Patients with Von Hippel-Lindau Disease.

  2025cites this paper
• Multisystemic Presentation of Von Hippel–Lindau Disease Revealed by Pheochromocytoma and Takotsubo Syndrome

  2025cites this paper
• Case report: Von Hippel-Lindau syndrome with multisystem involvement: a therapeutic dilemma

  2025cites this paper
• The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma

  2025cites this paper
• Surgical outcomes of partial adrenalectomy for pheochromocytoma: A systematic review and meta-analysis

  2025cites this paper
• Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease.

  2025cites this paper
• Pheochromocytoma and Paragangliomas: Current Management Strategies.

  2025cites this paper
• Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations

  2025cites this paper
• Tratamiento farmacológico de las neoplasias asociadas con la enfermedad de von Hippel-Lindau. Revisión Sistemática

  2025cites this paper
• Update on Surveillance in Von Hippel-Lindau Disease.

  2025cites this paper
• A Rare Sporadic Endolymphatic Sac Tumors: a case report and literature review

  2025cites this paper
• Maladie de von Hippel-Lindau

  2025cites this paper
• Risk Analysis of Retinal Hemangioblastomas in Nonadvanced Stages of von Hippel–Lindau Syndrome Using Ultra-widefield Imaging: The ULTRA von Hippel–Lindau Study

  2025cites this paper
• Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors

  2025cites this paper
• Advancing the Landscape of Clinical Actionability in Von Hippel–Lindau Syndrome: An Evidence-Based Framework from the INT2GRATE Oncology Consortium

  2025cites this paper
• Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma

  2024cites this paper
• A Narrative Review of Pheochromocytoma in VHL

  2024cites this paper
• A diagnostic approach to neurocutaneous syndromes

  2024cites this paper
• Hypertensive retinopathy as a presenting sign in phaeochromocytoma associated with Von Hippel–Lindau disease in an adolescent: A case report and literature review

  2024cites this paper
• CT-derived radiomics predict the growth rate of renal tumours in von Hippel-Lindau syndrome.

  2024cites this paper
• Non-malignant features of cancer predisposition syndromes manifesting in childhood and adolescence: a guide for the general pediatrician

  2024cites this paper
• Difficulties in Differentiation of Endolymphatic Sac Tumor That Extends Into Pontocerebellar Angle from Metastatic Tumors

  2024cites this paper
• Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel–Lindau?

  2024cites this paper
• Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery

  2024cites this paper
• Surgical management and prognostic factors for Endolymphatic Sac Tumor: a single-institute experience with a systematic review.

  2024cites this paper
• Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome

  2024cites this paper
• Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: A systematic review and single-arm meta-analysis.

  2024cites this paper
• Genetics, Pathophysiology, and Current Challenges in Von Hippel–Lindau Disease Therapeutics

  2024cites this paper
• Saturation genome editing maps the functional spectrum of pathogenic VHL alleles

  2024cites this paper
• Single Stage Bilateral Adrenalectomy (Cortical-Sparing) and Pancreatectomy (Corpus-Sparing) in a Patient with Von Hippel-Lindau Disease

  2024cites this paper
• Molecular Genetics of Pheochromocytoma/Paraganglioma.

  2024cites this paper
• Genotype-phenotype correlation of ocular von Hippel-Lindau disease in Koreans

  2024cites this paper
• Stereotactic Radiotherapy of VHL-Associated hemangioblastomas: A Family Case Report and Literature Review

  2024cites this paper
• Validation and Evaluation of 5 Scoring Systems for Predicting Metastatic Risk in Pheochromocytoma and Paraganglioma

  2024cites this paper
• Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease

  2024cites this paper
• Germline variants in the Von Hippel-Lindau tumor suppressor gene in Cuban patients

  2024influential citation
• Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.

  2024cites this paper
• Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series

  2024cites this paper
• Loss of VHL-mediated pRb regulation promotes clear cell renal cell carcinoma

  2024cites this paper
• Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI

  2024cites this paper
• Prevalence of Neurological Symptoms and Imaging Findings in Von Hippel–Lindau Patients Referred to Rasool Akram Hospital, 2018–2021

  2024cites this paper
• Late-Onset Manifestations of Von Hippel-Lindau Syndrome: A Case Report

  2024cites this paper
• Metabolomic landscape of renal cell carcinoma in von Hippel-Lindau syndrome in a Chinese cohort

  2024cites this paper
• Spinal cord hemangioblastomas in von Hippel–Lindau disease

  2024cites this paper
• Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

  2023cites this paper
• Management of Renal Malignancies in Von Hippel-Lindau Syndrome: Lessons Learned from a Series of Six Patients from Sri Lanka.

  2023cites this paper
• The Epidemiology of Brain and Spinal Cord Tumors.

  2023cites this paper
• Sunitinib Treatment of VHL C162F Cells Slows Down Proliferation and Healing Ability via Downregulation of ZHX2 and Confers a Mesenchymal Phenotype

  2023cites this paper
• Update of the UMD-VHL database: classification of 164 challenging variants based on genotype–phenotype correlation among 605 entries

  2023cites this paper
• Monogenic Kidney Diseases in Kidney Transplantation

  2023cites this paper
• A nonsense mutation in VHL causing Von Hippel-Lindau syndrome in a large Chinese family—a genetic study of familial neoplastic disease

  2023cites this paper
• The Paraganglioma of the Bladder in a Patient with Von Hippel-Lindau Syndrome

  2023cites this paper
• State of the Science and Ethical Considerations for Preimplantation Genetic Testing for Monogenic Cystic Kidney Diseases and Ciliopathies.

  2023cites this paper
• Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease

  2023cites this paper
• The potential of targeting cuproptosis in the treatment of kidney renal clear cell carcinoma.

  2023cites this paper
• Outcomes of and indications for renal transplantation in patients with von Hippel Lindau disease.

  2023cites this paper
• Preoperative Renal Parenchyma Volume as a Predictor of Kidney Function Following Nephrectomy of Complex Renal Masses

  2023cites this paper
• von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations.

  2023cites this paper
• Neurocutaneous Disorders in Pregnancy

  2023influential citation
• von Hippel–Lindau syndrome and steroid cell tumor of the ovary: A case report

  2023cites this paper
• Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma.

  2023cites this paper